- Monographie de SPEVIGO®, Boehringer Ingelheim (Canada) Ltée, 31 juillet 2024.
- Choon SE, et al. Study protocol of the global Effisayil 1 Phase II, multicentre, randomized, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open 2021;11:e043666 doi:10.1136/bmjopen-2020-043666.
- Morita A, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalized pustular psoriasis flares (Effisayil 2): an international, multicentre, randomized, placebo-controlled trial. Lancet 2023;402(10412):1541–51.
- Supplément à : Morita A, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalized pustular psoriasis flares (Effisayil 2): an international, multicentre, randomized, placebo-controlled trial. Lancet 2023; publié en ligne le 19 sept. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01378-8/abstract.
- Données en dossier. Boehringer Ingelheim, 11 septembre 2024.
